I hereby certify that this correspondence is being filed via EFS-Web with the United States Patent and Trademark Office				
on				
TOWNSEND	and TOWNSEND and CREW LLP			
By:	/Brien M. Bergner/			
•	Brien M. Bergner			

Attorney Docket No.: 082368-008500US Client Reference No.: ONC-A0310P-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NAKAMURA and FURUKAWA

Application No.: 10/586,987

Filing Date:

Int'l. Filing Date: January 21, 2005

For: METHODS OF DETECTING METHYL TRANSFERASE ACTIVITY AND METHODS OF SCREENING FOR METHYL TRANSFERASE ACTIVITY

**MODULATORS** 

Confirmation No.: 7942

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and

**§1.98** 

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In compliance with the requirements of 37 CFR \$1.98(a)(2), a copy of U.S. reference 0001 is not enclosed; copies of references 0002-0004, 0006, 0008-0012, 0014-0016, and 0018-0022 are enclosed.

Copies of references 0005, 0007, 0013, and 0017 are not provided since they were cited in the International Search Report, and as such, should have been provided by the WIPO

NAKAMURA and FURUKAWA

Application No.: 10/586,987

Page 2

•

under the exchange program between the USPTO, the EPO, and the JPO. A copy of the Search

Report is enclosed.

It is respectfully requested that the cited references be expressly considered

during the prosecution of this application, and the references be made of record therein and

appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the

information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses

all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the

undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit

any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

PATENT

/Kevin Bastian/

Kevin Bastian Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, Eighth Floor

San Francisco, California 94111-3834

Tel: 415-576-0200

Fax: 415-576-0300

KLB:bmb

_						
Substitute for form 1449A&B/PTO				Complete if Known		
				Application Number	10/586,987	
INFO	RMATION DIS	CLOS	URE	Filing Date	January 21, 2005	
STAT	STATEMENT BY APPLICANT			First Named Inventor	Nakamura, Yusuke	
				Art Unit		
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	082368-008500US	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Initials* No.1 MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant				
	Number Kind Code <sup>2 (f known)</sup>				
	0001	US-2004-0235018 A1	11-25-2004	NAKAMURA, Yusuke, et al.	

	FOREIGN PATENT DOCUMENTS								
Examiner Cite		Fo	oreign Patent Do	cument	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	No.¹	Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages	T <sup>6</sup>	
	0002	WO	98/33904	A2, A3	08-06-1998	Biognostik Gesellschaft für Biomolekulare Diagnostik mbH			
	0003	wo	00/44900	A2	08-03-2000	Incyte Pharmaceuticals, Inc.			
	0004	wo	02/059377	A2	08-01-2002	Eos Biotechnology, Inc.		ĬΠ	
	0005	wo	02/090578	A2	11-14-2002	Cambridge University Technical Services Limited and Chroma Therapeutics Limited			
	0006	wo	03/010180	A1	02-06-2003	The Board of Trustees of the Leland Stanford Junior University			
	0007	wo	03/027143	A2	04-03-2003	Japan as represented by The President of the University of Tokyo and Oncotherapy Science, Inc.			
	0008	wo	2004/076623	A2	09-10-2004	Oncotherapy Science, Inc. and Japan as represented by The President of the University of Tokyo			

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	0009	DU, Yong, et al.; "Hypermethylation in Human Cancers of the <i>RIZ1</i> Tumor Suppressor Gene, a Member of a Histone/Protein Methyltransferase Superfamily;" <u>Cancer Research</u> ; November 15, 2001; pp. 8094-8099; 61:22.				
	0010	ECHEVERRI, Chris, et al.; "siRNA Design: It's All in the Algorithm;" <u>Ambion.com; TechNotes;</u> 11:3; [http://www.ambion.com/techlib/tn/113/14.html].				
	0011	FU, Tie-Bo and John Taylor; "The RNAs of Hepatitis Delta Virus Are Copied by RNA Polymerase II in Nuclear Homogenates;" <u>Journal of Virology;</u> December 1993; pp. 6965- 6972; 67:12.				

Examiner	Date	
	Date	
Signature	Considered	
Olgitatuic	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known		
				Application Number	10/586,987	
INFO	PRMATION DIS	CLOS	URE	Filing Date	January 21, 2005	
STA	STATEMENT BY APPLICANT			First Named Inventor	Nakamura, Yusuke	
				Art Unit		
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number 082368-008500US		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	0012	HAMAMOTO, Ryuji, et al.; "ZNFN3A1, a novel gene that promotes growth in hepatocellular carcinoma;" Proceedings of the Annual Meeting of the American Association for Cancer Research; March 2002; 43; 13; #63.				
	0013	HAMAMOTO, Ryuji, et al.; "SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells;" Nature Cell Biology; August 2004; pp. 731-740; 6:8.				
	0014	LI, W. B., et al.; "Full-length cDNA libraries and normalization;" EMBL Accession No. AL557360; February 11, 2001.				
	0015	LÜKING, Angelika, et al.; "The Protein Family of RNA Helicases;" <u>Critical Reviews in</u> <u>Biochemistry and Molecular Biology</u> ; 1998; pp. 259-296; 33:4.				
	0016	NAKAJIMA, Tohsihiro, et al.; "RNA Helicase A Mediates Assocation of CBP with RNA Polymerase II;" <u>Cell</u> ; September 19, 1997; pp. 1107-1112; 90:6.				
	0017	REA, Stephen, et al.; "Regulation of chromatin structure by site-specific histone H3 methyltransferases;" Nature; August 10, 2000; pp. 593-599; 406:6796.				
	0018	STOCKAND, James D., et al.; "S-Adenosyl-L-homocysteine Hydrolase Regulates Aldosterone-induced Na <sup>+</sup> Transport;" <u>The Journal of Biological Chemistry;</u> February 5, 1999; pp. 3842-3850; 274:6.				
	0019	STRAHL, Brian D., et al.; "Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in <i>Tetrahymena</i> ;" <u>Proceedings of the National Academy of Sciences of the United States of America (PNAS)</u> ; December 21, 1999; pp. 14967-14972; 96:26.				
	0020	SUGANO, Sumio, et al.; "NEDO human cDNA sequencing project;" EMBL Accession No. AK024733; September 29, 2000.				
	0021	GeneCards; SMYD3; [http://www.genecards.org/cgi-bin/carddisp.pl?gene=SMYD3&search=gc01m242239&suff=txt]; June 16, 2006.				
	0022	GENESEQ; Accession No. RS10672134; November 13, 2003.				

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.